Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Bimatoprost (lashes) wins 1 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Prescription topical. Bimatoprost 0.03% is applied once daily as a thin line to the skin of the UPPER eyelid margin at the lash base (not to the lower lid, and avoid getting it in the eye), using a fresh applicator per eye. Continuous use is needed to maintain results. Use under a clinician, especially if you have glaucoma or take prostaglandin eye drops. There is no oral or systemic use. This library does not provide an ingestion protocol.
evening
Bimatoprost 0.03% solution (Latisse) with single-use applicators, under a clinician
Prescription topical. Hydroquinone is used at 2-4% (often as the triple-combination with a retinoid and a mild corticosteroid), applied to pigmented areas usually at night, in time-limited courses (commonly with treatment breaks) under clinician supervision, always with daily sunscreen. There is no oral or systemic use. Avoid indefinite continuous use because of ochronosis risk. This library does not provide an ingestion protocol.
evening
Hydroquinone 2-4% cream or the triple-combination (with retinoid + mild steroid), under a clinician
Throughout
8-16 weeks
2-6 months after stopping
Weeks to months
Throughout
8-12 weeks
Throughout
Months to years
Long-term safety and efficacy of bimatoprost solution 0.03% application to the eyelid margin for the treatment of idiopathic and chemotherapy-induced eyelash hypotrichosis: a randomized controlled trial.
Br J Dermatol (2015) · Rct
1-year double-masked RCT: composite primary endpoint (Global Eyelash Assessment + satisfaction) met for bimatoprost vs vehicle in idiopathic (40.2% vs 6.8%) and post-chemotherapy (37.5% vs 18.2%) hypotrichosis
Bimatoprost for eyelash growth in Japanese subjects: two multicenter controlled studies.
Aesthetic Plast Surg (2014) · Rct · n=209
Two double-masked vehicle-controlled RCTs (n=209: 173 idiopathic, 36 chemotherapy-induced) in Japanese subjects
The efficacy of topical prostaglandin analogs for hair loss: A systematic review and meta-analysis.
Front Med (Lausanne) (2023) · Meta analysis
Meta-analysis of six placebo-controlled RCTs of topical prostaglandin analogs (incl. bimatoprost) for hair growth (lashes, brows, scalp)
Efficacy and safety of a new triple-combination agent for the treatment of facial melasma.
Cutis (2003) · Rct · n=641
Two pooled 8-week multicenter randomized investigator-blind trials (n=641) of the triple-combination (tretinoin 0.05% + hydroquinone 4% + fluocinolone 0.01%) vs the three dual pairings
Efficacy and safety of a novel triple combination cream compared to Kligman's trio for melasma: A 24-week double-blind prospective randomized controlled trial.
J Eur Acad Dermatol Venereol (2023) · Rct · n=40
24-week double-blind RCT (n=40) using Kligman's trio (hydroquinone + retinoic acid + corticosteroid) as the active gold-standard comparator
Systematic review of randomized controlled trials on interventions for melasma: an abridged Cochrane review.
J Am Acad Dermatol (2014) · Systematic review
Abridged Cochrane review of 20 RCTs (2125 participants) across 23 melasma treatments
Bimatoprost (lashes) has a higher evidence score (8/10 vs 7/10) and wins in 1 of 3 categories.
No known interactions between Bimatoprost (lashes) and Hydroquinone have been documented in our database. However, always consult a healthcare provider before combining supplements.